CP-CTNet_CLO-Mayo Clinic Phase I Double-Blind, Placebo-Controlled Trial of 27 mg Dolcanatide (SP-333) to Demonstrate Colorectal Bioactivity in Healthy Volunteers Cancer Prevention and Control CIRB Completed Completed